Related Experiment Videos
Chemotherapy of acute bone and joint infections
Abstract:
A series of 72 cases of acute osteomyelitis and acute septic arthritis has been presented. Operative intervention was necessary in 71% of our cases. All patients were treated with antibiotics. The initial antibiotic treatment in 39% of the cases was a combination of trimethoprim and sulfamethoxazole (TMP/SMX). This combination gave the lowest average time for subsidence of general symptoms and local signs. Staphylococcus aureus was the causative organism in 87% of our cases. Streptococcus pyogenes and Pneumococcus were the other causative organisms. Over half of the S. aureus infections were resistant to penicillin but none were resistant to TMP/SMX. Considering the low toxicity, good clinical response, lack of bacterial resistance, presence of synergy and broad antibacterial spectrum, the use of TMP/SMX is recommended in acute pyogenic bone and joint infections.
Insights
Trimethoprim-sulfamethoxazole (TMP/SMX) effectively treated acute osteomyelitis and septic arthritis, showing faster symptom relief. This antibiotic combination demonstrated low toxicity and no bacterial resistance in Staphylococcus aureus infections.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Acute osteomyelitis and septic arthritis are serious infections requiring prompt treatment.
- Antibiotic selection is crucial, especially with rising bacterial resistance.
- Staphylococcus aureus is a common pathogen in bone and joint infections.
Purpose of the Study:
- To evaluate the efficacy of trimethoprim-sulfamethoxazole (TMP/SMX) in treating acute pyogenic bone and joint infections.
- To compare TMP/SMX with other initial antibiotic treatments.
- To assess bacterial resistance patterns in causative organisms.
Main Methods:
- Retrospective analysis of 72 cases of acute osteomyelitis and septic arthritis.
- Documentation of operative interventions, antibiotic treatments, and clinical outcomes.
- Identification of causative organisms and their antibiotic susceptibility.
Main Results:
- Operative intervention was required in 71% of cases.
- Initial TMP/SMX treatment (39% of cases) showed the shortest subsidence time for general and local symptoms.
- Staphylococcus aureus (87% of cases) was the predominant pathogen; over half were penicillin-resistant but none were TMP/SMX resistant.
Conclusions:
- TMP/SMX is a recommended antibiotic for acute pyogenic bone and joint infections due to its efficacy, low toxicity, and broad spectrum.
- TMP/SMX demonstrated superior clinical response and lack of bacterial resistance compared to other treatments.
- The synergistic action and antibacterial spectrum of TMP/SMX support its use in managing these severe infections.